The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies

As many patients ultimately relapse after chimeric antigen receptor (CAR) T-cell therapy, identification of alternative targets is currently being evaluated. Substantial research efforts are underway to develop new targets. The transferrin receptor (TfR) is prevalently expressed on rapidly prolifera...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Immunol
Auteurs principaux: Guo, Zilong, Zhang, Yirui, Fu, Mingpeng, Zhao, Liang, Wang, Zhen, Xu, Zhuoshuo, Zhu, Huifen, Lan, Xiaoli, Shen, Guanxin, He, Yong, Lei, Ping
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2021
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8039461/
https://ncbi.nlm.nih.gov/pubmed/33854512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.652924
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires